Articles related to GLP-1 RECEPTOR AGONISTS

A case report describes duodenal ulcer perforation in a woman receiving tirzepatide for weight loss, occurring shortly after dose escalation, though important confounders prevent conclusions about a causal drug relationship.

Three adults receiving semaglutide or tirzepatide preserved or increased lean soft tissue while losing weight alongside resistance training and protein-focused diets, although the uncontrolled case series cannot determine which strategies produced these outcomes.

Semaglutide use before or during pregnancy was associated with greater gestational weight gain and several adverse outcomes in a retrospective cohort, although similar findings among former users complicate attribution to direct fetal exposure.

Semaglutide use was associated with lower psychiatric hospitalization and bipolar-relapse hospitalization risks among Swedish adults with bipolar disorder receiving antidiabetic medication, although the observational findings did not establish a therapeutic effect.

An editorial in Obesity highlights emerging evidence that GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, while emphasizing unresolved questions regarding muscle preservation, nutritional status, and potential effects on substance use disorders.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.